In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples